MedPath

Thiotepa

Generic Name
Thiotepa
Brand Names
Tepadina, Thiotepa Riemser
Drug Type
Small Molecule
Chemical Formula
C6H12N3PS
CAS Number
52-24-4
Unique Ingredient Identifier
905Z5W3GKH
Background

N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. Its main toxicity is myelosuppression.

Indication

ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.

Associated Conditions
Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
Clinical Trials
Related News

Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplant (HSCT) For Lymphoma

Phase 1
Withdrawn
Conditions
Lymphoma
Interventions
Procedure: Allogeneic stem cell transplantation
First Posted Date
2016-03-31
Last Posted Date
2017-03-22
Lead Sponsor
Massachusetts General Hospital
Registration Number
NCT02724904
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Allogeneic Stem Cell Transplantation for Children With CML

Phase 2
Completed
Conditions
Chronic Myeloid Leukemia
Interventions
Biological: bone marrow or peripheral blood stem cells
First Posted Date
2016-03-14
Last Posted Date
2021-04-15
Lead Sponsor
St. Anna Kinderkrebsforschung
Target Recruit Count
13
Registration Number
NCT02707393
Locations
🇦🇹

Universitätsklinik für Kinder- und Jugendheilkunde, Graz, Austria

🇨🇿

Hospital Motol, Department of Pediatric Hematology and Oncology, BMT Unit, Praha, Czechia

🇦🇹

St. Anna Kinderspital, Wien, Austria

and more 1 locations

URMC Related Haplo-identical Donor BMT

Phase 1
Completed
Conditions
Immune Deficiencies
Solid Tumors
Myelofibrosis
Multiple Myeloma
Lymphoma
Hematological Disease
Interventions
Radiation: Total Body Irradiation 1200 cGy
Procedure: Stem Cell Infusion
Drug: Pre-Stem Cell Infusion Mesna
Drug: Post-Stem Cell Infusion Mesna
First Posted Date
2016-01-21
Last Posted Date
2021-11-03
Lead Sponsor
University of Rochester
Target Recruit Count
74
Registration Number
NCT02660281
Locations
🇺🇸

Wilmot Cancer Institute, Rochester, New York, United States

A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors

Early Phase 1
Terminated
Conditions
Neuroepithelial Tumor
Solid Tumor
Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
Procedure: Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy
Drug: Keratinocyte Growth Factor
First Posted Date
2016-01-12
Last Posted Date
2017-08-17
Lead Sponsor
Montefiore Medical Center
Target Recruit Count
1
Registration Number
NCT02653196
Locations
🇺🇸

The Children's Hospital at Montefiore, The Bronx, New York, United States

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Phase 2
Recruiting
Conditions
Neuroblastoma
Interventions
Biological: Autologous Stem Cell Infusion
Biological: Granulocyte colony stimulating factor
First Posted Date
2015-11-16
Last Posted Date
2024-07-19
Lead Sponsor
Masonic Cancer Center, University of Minnesota
Target Recruit Count
12
Registration Number
NCT02605421
Locations
🇺🇸

Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies

Phase 2
Conditions
Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Multiple Myeloma
Non Hodgkin Lymphoma
Interventions
First Posted Date
2015-07-24
Last Posted Date
2016-04-20
Lead Sponsor
Sheba Medical Center
Target Recruit Count
24
Registration Number
NCT02507479
Locations
🇮🇱

Chaim Sheba Medical Center, Tel-Hashomer, Israel

Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies

Phase 2
Conditions
Leukemia, Myeloid
Interventions
Drug: IV Anti-thymocyte globuline
First Posted Date
2015-01-07
Last Posted Date
2018-08-13
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
31
Registration Number
NCT02333838
Locations
🇫🇷

Hôpital de Brabois, Hématologie Clinique et thérapie cellulaire, Vandoeuvre les Nancy, France

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Phase 2
Completed
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Radiation: whole brain radiotherapy
First Posted Date
2014-12-31
Last Posted Date
2024-07-29
Lead Sponsor
International Extranodal Lymphoma Study Group (IELSG)
Target Recruit Count
76
Registration Number
NCT02329080
Locations
🇮🇹

IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy

🇮🇹

Villa Sofia - Cervello, Palermo, Italy

🇨🇿

Facultni nemocnice, Brno, Czechia

and more 33 locations

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

Phase 2
Terminated
Conditions
Acute Lymphoblastic Leukemia (ALL)
Acute Myeloid Leukemia (AML)
Myeloid Sarcoma
Chronic Myelogenous Leukemia (CML)
Juvenile Myelomonocytic Leukemia (JMML)
Myelodysplastic Syndrome (MDS)
Non-Hodgkin Lymphoma (NHL)
Interventions
Biological: G-CSF
Biological: Interleukin-2
Biological: Natural killer cell therapy
Biological: T-cell depleted HPC transplant
Biological: CD45RA-depleted HPC transplant
First Posted Date
2014-10-08
Last Posted Date
2017-05-30
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
12
Registration Number
NCT02259348
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD

Phase 2
Active, not recruiting
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Donor
Recurrent Acute Lymphoblastic Leukemia
Refractory Acute Myeloid Leukemia
Childhood Acute Myeloid Leukemia in Remission
Myelodysplastic Syndrome With Excess Blasts-2
Recurrent Childhood Acute Lymphoblastic Leukemia
Recurrent Childhood Acute Myeloid Leukemia
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Acute Biphenotypic Leukemia
Interventions
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Other: Laboratory Biomarker Analysis
Procedure: Peripheral Blood Stem Cell Transplantation
Radiation: Total-Body Irradiation
First Posted Date
2014-08-20
Last Posted Date
2025-04-23
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
84
Registration Number
NCT02220985
Locations
🇺🇸

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy